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Parthenolide generates reactive oxygen species and
autophagy inMDA-MB231 cells. A soluble parthenolide
analogue inhibits tumour growth and metastasis in a
xenograft model of breast cancer
A D’Anneo1,5,6, D Carlisi2,5,6, M Lauricella2, R Puleio3, R Martinez1, S Di Bella3, P Di Marco3, S Emanuele2, R Di Fiore1, A Guercio3,
R Vento1,4 and G Tesoriere*,1,4
Triple-negative breast cancers (TNBCs) are clinically aggressive forms associated with a poor prognosis. We evaluated the
cytotoxic effect exerted on triple-negative MDA-MB231 breast cancer cells both by parthenolide and its soluble analogue
dimethylamino parthenolide (DMAPT) and explored the underlying molecular mechanism. The drugs induced a dose- and time-
dependent decrement in cell viability, which was not prevented by the caspase inhibitor z-VAD-fmk. In particular in the first hours
of treatment (1–3 h), parthenolide and DMAPT strongly stimulated reactive oxygen species (ROS) generation. The drugs induced
production of superoxide anion by activating NADPH oxidase. ROS generation caused depletion of thiol groups and glutathione,
activation of c-Jun N-terminal kinase (JNK) and downregulation of nuclear factor kB (NF-kB). During this first phase, parthenolide
and DMAPT also stimulated autophagic process, as suggested by the enhanced expression of beclin-1, the conversion of
microtubule-associated protein light chain 3-I (LC3-I) to LC3-II and the increase in the number of cells positive
to monodansylcadaverine. Finally, the drugs increased RIP-1 expression. This effect was accompanied by a decrement of
pro-caspase 8, while its cleaved form was not detected and the expression of c-FLIPS markedly increased. Prolonging the
treatment (5–20 h) ROS generation favoured dissipation of mitochondrial membrane potential and the appearance of necrotic
events, as suggested by the increased number of cells positive to propidium iodide staining. The administration of DMAPT in
nude mice bearing xenografts of MDA-MB231 cells resulted in a significant inhibition of tumour growth, an increment of animal
survival and a marked reduction of the lung area invaded by metastasis. Immunohistochemistry data revealed that treatment with
DMAPT reduced the levels of NF-kB, metalloproteinase-2 and -9 and vascular endothelial growth factor, while induced
upregulation of phosphorylated JNK. Taken together, our data suggest a possible use of parthenolide for the treatment
of TNBCs.
Cell Death and Disease (2013) 4, e891; doi:10.1038/cddis.2013.415; published online 31 October 2013
Subject Category: Cancer
Triple-negative breast cancers (TNBCs) are clinically aggres-
sive forms of breast cancer,1 which do not express oestrogen,
progesterone and HER-2/neu receptors.2 They are unrespon-
sive to endocrine agents or trastuzumab3 and are
typically treated with a combination of therapies such as
surgery, radiation therapy and chemotherapy.4–6 As standard
chemotherapy with anthracyclines, taxanes and platinum
agents is characterised by a high rate of acquired
resistance,5,7–9 a novel treatment strategy for TNBCs is
urgently needed.
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Parthenolide, a sesquiterpene lactone found in Tanacetum
parthenium, known for its anti-inflammatory activity,10 is
considered as a novel anti-tumour agent. Parthenolide
induces cytotoxicity in prostate,11 pancreatic12 and colorectal
cancers,13 multiple myeloma14 and leukaemia cells,15 but is
ineffective in normal tissues.16 It exerts antitumor activity also
in breast cancer cells,17 inducing DNA-binding inhibition of
two transcription factors, the nuclear factor kB (NF-kB)
and the signal transducer and activator of transcription 3
(STAT-3), together with reactive oxygen species (ROS)
generation and c-Jun N-terminal kinase (JNK) activation.
Finally, parthenolide, in combination with docetaxel, improves
survival in a xenograft model of breast cancer and reduces
lung metastases.18 However, the mechanisms of these
effects are unknown today.
Recently, we showed that parthenolide exerts cytotoxicity
on osteosarcoma and melanoma cells19 through a caspase-
independent mechanism correlated with ROS generation.
The present paper shows that parthenolide induces
in MDA-MB231 cells, the most studied TNBC cells, a
caspase-independent form of death, stimulating oxidative
stress and autophagy.
Despite the high efficacy of parthenolide in vitro, its
pharmacological use is difficult owing to the scarce solu-
bility.20 Recently, a dimethylamino analogue of parthenolide
(DMAPT) has been generated, which improves solubility
and bioavailability and exhibits an acceptable toxicological
profile in animal studies.21,22 DMAPT eradicates primary
leukaemia stem cells21 and suppresses in vivo the growth of
prostate,22 lung and bladder cancers,23 by targeting NF-kB
and generating ROS.
In this paper, we also demonstrate that DMAPT significantly
decreases tumour growth in mice bearing xenografts of MDA-
MB231 cells and enhances survival of treated mice. Moreover,
immunohistochemical studies show that DMAPT decreases
in vivo the levels of metalloproteinase-2 (MMP-2), metallo-
proteinase-9 (MMP-9) and vascular endothelial growth factor
(VEGF), all factors involved in metastatic events.
Results
Parthenolide effect on cell viability and intracellular
calcium level. Treatment with parthenolide or DMAPT
inhibited viability of MDA-MB231 cells, assessed by MTT
method, in a dose- and time-dependent manner (Figures 1a
and b). After 16 h of exposure to 25 mM cell viability
decreased by 64% with parthenolide and 70% with DMAPT.
N-acetylcysteine (NAC; 2 mM), an effective scavenger of free
radicals, suppressed this effect with both the drugs, while
50 mM necrostatin-1 (Nec-1), an inhibitor of receptor-
interacting protein-1 (RIP-1) kinase,24 caused a partial
reduction. Conversely, 100mM z-VAD-fmk, a general
inhibitor of caspases, did not modify parthenolide or DMAPT
effect (Figure 1c).
To ascertain the cause of the inhibitory effect and to
differentiate apoptotic and necrotic cells, the cells were
stained with Annexin V-fluorescein isothiocyanate (FITC)
and propidium iodide (PI) and analysed by flow cytometry at 8
and 16 h of treatment with 25 mM parthenolide (Figure 1d) or
DMAPT (Supplementary Figure S2A). Figure 1d shows that
already at 8 h cells undergoing necrosis (Annexin V-negative/
PI-positive cells, C1) amounted to 37.8% of the total. However
a population of cells positive to both Annexin V and PI (C2)
was observed at 8 h (14.3%) and increased at 16 h (24.6%).
These cells could be late apoptotic or necrotic dead cells.
We concluded that they are necrotic dead cells, because 8 or
16 h of treatment did not significantly modify the percentage of
early apoptotic cells (Annexin V-positive/PI-negative
cells, C4) from the control. Moreover, Nec-1, which inhibits
RIP-1-induced necrosis, strongly reduced the percentage of
cells positive to both Annexin V and PI.25
Next we analysed the drug impact on cell cycle. After 4 h of
exposure fraction of cells in G2/M increased from 15 to 35%
with both parthenolide (Supplementary Figure S1A) and
DMAPT (Supplementary Figure S2B). These effects per-
sisted until 16 h of treatment.
Moreover, parthenolide induced morphological changes in
MDA-MB231 cells. Under light microscopy control cells
exhibited an adhesive and widened morphology. At 1 h of
exposure to 25 mM the cells assumed a rounded shape and at
4 h were deprived of anchorage and floated in the medium
(Figure 1e). All these effects were suppressed by 2 mM NAC.
Parthenolide treatment rapidly increased intracellular
Ca2þ level. The effect, appeared at 30 min of exposure to
15 mM parthenolide, reached the maximum at 1 h and then
declined at 2 and 3 h (Figure 1F).
Parthenolide induces production of radical species.
NADPH oxidase (NOX) is a multisubunit enzyme,
which catalyses the transfer of an electron to O2 to generate
O2
 , a highly ROS.
Parthenolide is known to activate NOX and to mediate
intense oxidative stress in prostate cancer cells26 and multiple
myeloma cells.27 To ascertain whether parthenolide stimu-
lated NOX also in MDA-MB231 cells, we evaluated its effect
on superoxide anion production. Analysis performed
by dihydroethidium (DHE) revealed by direct estimation using
fluorescence microscope the appearance of intense red
fluorescence after 2–6 h of treatment with 25 mM parthenolide.
This effect was abrogated both by apocynin, a specific
inhibitor of NOX activity,28,29 and BAPTA-AM,30 an intra-
cellular Ca2þ chelator. In conclusion, parthenolide stimulated
NOX activation through a mechanism mediated by Ca2þ .
Figure 2a shows the results obtained at 3 h of treatment.
A group of oxidoreductases, known as superoxide dis-
mutases, catalyse the dismutation of O2
 into oxygen and
H2O2, a less aggressive form of ROS. The fluorochrome H2-
DCFDA, a general indicator of cellular ROS level, was used to
ascertain ROS level by direct estimation using fluorescence
microscope. A time course study (Figures 2b and c) with
15 mM parthenolide showed that ROS generation rapidly
increased, reaching the maximum at 1–3 h, when 90% of cells
exhibited green fluorescence. Then the effect declined to 30%
at 16 h of exposure. ROS generation (Figures 2d and e) was
suppressed both by NAC and BAPTA-AM, whatever the time
of treatment was. These results indicated an important role
exerted by Ca2þ in ROS generation. Moreover apocynin, an
inhibitor of NOX activity, markedly reduced ROS level at 1 h of
treatment, while at 8 h a lower effect was found. Therefore, in
the first phase of treatment, ROS generation primarily
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depended on NOX activation. Differently Rotenone and
trifluorocarbonylcyanide phenylhydrazone (FCCP),31 which
inhibit mitochondrial electron transport system, produced a
little effect at 1 h and a greater effect at 8 h of exposure,
suggesting that mitochondrial production of ROS increased in
the second phase of treatment (Figures 2d and e).
Figure 1 Treatment with parthenolide or DMAPT inhibits proliferation and induces necrosis of MDA-MB231 cells. (a–c) Cytotoxic effects exerted by both parthenolide and
DMAPT on cell viability. Cells (8 103/well) were treated (a) for 16 h with different doses of parthenolide or DMAPT and (b) for various times with 25mM parthenolide or 25mM
DMAPT. (c) Cells were treated for 16 h with 25mM parthenolide or 25mMDMAPT without or with 2 mM NAC, 100 mM z-VAD-fmk, 50mM Nec-1. Cell viability was assessed by
MTT assay, as reported in Materials and Methods. (d) Analysis by Annexin V/PI double-staining assay of parthenolide effects. Cells (2 105/well) were treated for 8 or 16 h
with 25mM parthenolide without or with 50 mM Nec-1. After treatment, cells were stained with annexin V-FITC and PI and analysed by flow cytometry. C1 is related to necrotic
cells (Annexin V-FITC-negative and PI-positive), C2 were cells in end stage of apoptosis or necrotic dead cells (Annexin V-FITC-positive and PI-positive), C3 were viable cells
(Annexin V-FITC-negative and PI-negative) and finally C4 is related to cells undergoing early apoptosis (Annexin V-FITC-positive and PI-negative). (e) Morphological effects
induced by parthenolide, observed under light microscopy at  200 magnification. Cells (8 103/well) were treated for 4 h with 25mM parthenolide without or with 2 mM NAC.
Scale bar, 5 mm. (f) The effects of parthenolide on the levels of intracellular Ca2þ . Cells (2 105/well) were treated with 15mM parthenolide for various times. At the end, cells
were loaded with 5 mM Fluo-3 AM for 60min and then immediately analysed using flow cytometry. In (a–c) values are the means of three independent experiments±S.E.
*Po0.01 versus untreated control. In (d–f) the results are representative of three independent experiments
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Results concerning generation of both superoxide anion
and ROS were confirmed by cytofluorimetric analysis either
using parthenolide (Supplementary Figure S1B, C) or DMAPT
(Supplementary Figure S2C, D).
Parthenolide activates ERK1/2, JNK and RIP-1. Western
blotting analysis (Figure 3a) demonstrated that parthenolide
increased in a dose-dependent manner the levels of
phosphorylated ERK1/2 (p-ERK1/2), phosphorylated JNK
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(p-JNK) and RIP-1. These effects appeared at 1 h of
treatment and increased at 2–4 h. Parthenolide effect on
p-ERK1/2 level was prevented by U0126, an inhibitor of the
mitogen-activated protein kinase kinase 1/2 (MEK1/2),32
which is the upstream ERK1/2 regulator.33 Instead apocynin,
NAC and finally SP600125, a specific inhibitor of JNK
activity,34 did not modify parthenolide effect on p-ERK1/2
level (Figure 3a). Therefore, NOX and JNK activation
as well as ROS generation lie downstream of ERK1/2
activation. This conclusion agrees with the finding of
Moon et al.,32 which demonstrated that ERK1/2 activation,
induced by MEK1/2, enhanced NOX transcription and ROS
generation.
Moreover, our results show that U0126, apocynin, NAC and
SP600125 prevented parthenolide effect on JNK activation
(Figure 3a), which therefore lies downstream of the activation
of ERK1/2 and NOX and the production of ROS. Con-
sequently, it seems possible that JNK activation was
stimulated by ERK1/2.
In addition, because none of the inhibitors modified
parthenolide effect on RIP-1 level (Figure 3a), stimulation of
RIP-1 expression seemed to be independent of ROS
production and activation of ERK1/2 and JNK.
Finally, also DMAPT increased the expression of p-JNK
and RIP-1, as shown in Supplementary Figure 2SE.
Parthenolide effects on caspases, c-FLIP and FADD.
We also investigated by western blotting analysis
whether parthenolide exerted some effects on the expression
of pro-caspases and the production of their active forms
(Figure 3b). Antibodies employed for this analysis detect both
the full-length forms of caspases and the active fragments
resulting from their cleavage. Parthenolide (25 mM)
decreased the levels of pro-caspases 3, 8 and 9. The effect
was observed already at 4 h and increased until 16 h of
exposure. Interestingly, the cleaved and active forms of
caspases were not detected also when the cells were
exposed for 16 h to parthenolide.
Figure 2 Parthenolide stimulates oxidative stress in MDA-MB231 cells. (a) Parthenolide induces production of superoxide anion. Cells (8 103/well) were treated for 3 h
with 25mM parthenolide alone or in the presence of 100mM apocynin or 10mM BAPTA-AM. At the end, after replacement of the culture medium with 100ml PBS, 20mM DHE
was added and the incubation was protracted for 10min. Oxidation of DHE by superoxide anion generates red fluorescence, which was visualised with a Leica microscope at
 200 magnification using a rhodamine filter. (b–e) Parthenolide induces ROS generation. Cells (8 103) were treated for various times with 15 mM parthenolide alone or in
the presence of various inhibitors. At the end, the medium was removed, 100ml of 50mM H2-DCFDA were added and the incubation was protracted for 30min at 37 1C. Then
the fluorochrome was substituted with 100 ml PBS and the analysis was performed after 20min. Oxidation of the fluorochrome produces green fluorescence, which was
visualised with a Leica microscope equipped with a DC300F camera at  200 magnification using a FITC filter. (b) Images of fluorescence microscopy showing ROS
generation induced by parthenolide at various times of treatment and (c) the relative percentages of cells with green fluorescence. (d) Images of fluorescence microscopy
showing the influence of various inhibitors on ROS generation induced by treatment for 1 and 8 h with parthenolide and (e) the relative percentages of cells with green
fluorescence. In (a, b and d), the results are representative of three independent experiments. Scale bar, 10 mm. In (c) and (e) values are the means of three independent
experiments±S.E. *Po0.01 versus untreated control
Figure 3 Western blotting analyses showing changes induced by parthenolide on the expression of various factors involved in the molecular mechanism of the drug. Cells
(2 105 cells/well) were treated for different times and with various doses of parthenolide without or with various inhibitors. At the end, the extracts were prepared and
submitted to western blotting analysis. (a) Parthenolide activates the expression of p-ERK1/2, p-JNK and RIP-1. (b) Changes induced by parthenolide on the levels of pro-
caspase 8, 3 and 9, c-FLIP and FADD. All the results are representative of three independent experiments
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Moreover, parthenolide increased the expression
of cellular FLICE-like inhibitory protein (c-FLIP). This
effect was much higher for c-FLIPS than c-FLIPL, and was
observed from 4 until 16 h of exposure. Conversely,
parthenolide lowered the level of Fas-associated
death domain (FADD) from 4 to 16 h of exposure
(Figure 3b). Similar results for caspase 8, c-FLIP and
FADD were found treating the cells with 25 mM DMAPT
(Supplementary Figure S2F).
Parthenolide causes depletion of intracellular thiols.
The observation that parthenolide rapidly increased ROS
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generation suggested to us that it can induce depletion of
intracellular thiols.
As Figure 4a shows basal level of GSH exhibited a modest
decrement in untreated cells during 16 h of incubation.
Conversely exposure to 25 mM parthenolide or DMAPT
progressively lowered GSH level, which at 16 h fell in both
the cases to only 10–15% of control. Experiments were also
performed to analyse the content of SH groups (free and
protein thiols), revealing that the drugs decreased the content
of free thiols similarly to GSH. Minor effects were observed for
protein thiols, as their level was reduced at 16 h of treatment to
about 30% of control both with parthenolide or DMAPT
(Figure 4a).
Parthenolide effect on NF-kB activity. NF-kB is known
to induce in tumour cells gene expression favouring
survival, angiogenesis and metastasis.35 Therefore,
targeting NF-kB represents a strategy in anticancer therapy,
which might be effective particularly in TNBC cells,
because the lack of oestrogen receptors might favour
NF-kB activity.36
Interestingly, parthenolide inhibits NF-kB activity in many
tumour cells,37,38 inducing cell death. We ascertained
(Figure 4b) by ELISA assay that DNA-binding activity of
p65, a subunit of NF-kB, decreased at 16 h of exposure to
4mM parthenolide or DMAPT by 25% and 30%, respectively,
while with both the drugs the highest decrement was observed
using 50 mM ( 75%). NAC (2 mM) partially prevented this
effect, suggesting that ROS generated by parthenolide
contributed to downregulate NF-kB activity.
Finally, treatment with 25 mM parthenolide or DMAPT for
16 h reduced p65 protein level. Also this effect was prevented
by 2 mM NAC (Figure 4c).
Parthenolide causes dissipation of mitochondrial
membrane potential and induces cell necrosis. We
investigated whether 25 mM parthenolide modified mitochon-
drial membrane potential (Dcm) by using fluorescent cationic
dye JC-1 (Figure 4d) and visualising fluorescence by a Leica
microscope (Wetzlar, Germany). At 4 h of treatment, red-
orange fluorescence prevailed on greenish fluorescence,
suggesting that most of cells were polarised. Then, greenish
fluorescence increased with the time, reaching the maximum
at 16 h, when most of cells were depolarised. Dissipation of
Dcm was suppressed by 2 mM NAC.
To ascertain the effect of parthenolide and DMAPT on
the induction of necrosis, cells were treated with PI, a
cell-impermeable nuclear dye, which stains the nuclei of cells
that have lost plasma membrane integrity and are considered
necrotic. With both the drugs (15mM), the percentage of
PI-positive cells increased with the time of treatment at first
slowly until 8 h, when only a 15% of PI-positive cells was
counted, then, more rapidly between 8–20 h, reaching at 20 h
a level of about 80% (Figure 4e). This effect was suppressed
by both NAC and Nec-1 (Figure 4f), suggesting that ROS
generation and RIP-1 activation exerted a central role in the
induction of cell necrosis.
Parthenolide induces autophagic process. Treatment
with 15 mM parthenolide produced autophagic vacuoles in
the cytoplasm of MDA-MB231 cells. Vacuoles were visua-
lised under fluorescence microscopy by staining with mono-
dansylcadaverine (MDC) as distinct dot-like structures.39
As Figures 5a and b show about 65% of cells were positive to
MDC test at 1 h of treatment. Then the effect increased up to
8 h, when positive cells reached 80%.
As above reported, parthenolide upregulated both p-JNK
and RIP-1 expression. As both SP600125 and Nec-1, which
inhibit activation of JNK and RIP-1 respectively, strongly
reduced the number of MDC-positive cells (Figure 5c), we
suggest that parthenolide effect on autophagy was mediated
by JNK and RIP-1. Moreover, also PI3K was needed for the
production of autophagic vacuoles as both 3-methyladenine
(3-MA) and wortmannin (PI3K inhibitors) reduced the number
of MDC-positive cells (Figure 5c).
Microtubule-associated protein light chain 3 (LC3) is
detected as two bands following SDS-PAGE: LC3-I,
a cytosolic form, and LC3-II, a form conjugated with
phosphatidylethanolamine present in autophagosomes.40
Parthenolide increased LC3-II level with a dose-dependent
effect, which was highest at 2 h of treatment. Moreover, the
effect was prevented by NAC and 3-MA and partially reduced
by SP600125 and Nec-1 (Figure 5d).
Beclin-1 has an essential role in autophagosome formation.
Its expression enhances during autophagy. However, its
function is inhibited by interaction with Bcl-2. Phosphorylation
of Bcl-2 by JNK41 causes the release of beclin-1,42 which can
exert its pro-autophagic role. Parthenolide treatment
increased beclin-1 expression with a dose-dependent effect,
which reached the maximum at 2 h and was suppressed by
NAC, SP600125 and Nec-1 and partially reduced by 3-MA
(Figure 5d). Treatment with DMAPT produced similar effects
on the expression of both LC3 and beclin-1 (Supplementary
Figure S2E).
Figure 4 (a) Parthenolide and DMAPT induce depletion of intracellular GSH and thiols. Cells (5 105/condition) were treated for various times with 25 mM parthenolide or
25mM DMAPT. At the end, GSH, free thiols and protein thiols were determined using colorimetric assays, as reported in Materials and Methods. Values are expressed as
nmol/105 cells. (b and c) The effects of parthenolide and DMAPT on NF-kB activity. (b) The drugs downregulated DNA-binding activity of p65. Cells (3 105/condition) were
treated for 16 h with various concentrations of parthenolide or DMAPT without or with 2mM NAC. The binding was quantified in nuclear extracts by an ELISA assay as reported
in Materials and Methods. (c) Western blotting analysis showing the effect of 25 mM parthenolide and DMAPT on the expression of p65 protein. Cells (2 105/condition) were
treated for 16 h with the drugs, without or with 2mM NAC. Cell lysates were prepared and subjected to western blotting as reported in Materials and Methods. (d) Parthenolide
induces mitochondrial depolarisation in MDA-MB231 cells. Cells (8 103/well) were treated for various times with 25 mM parthenolide. After exposure, the fluorochrome JC-1
was added for additional 15min. Depolarisation was indicated by the shift of fluorescence from red-orange to greenish. Merged images were visualised with a Leica
microscope at  200 magnification with fluorescent filters for FITC and rhodamine. Scale bar, 10 mm. The effect of parthenolide was prevented by 2mM NAC. (e and f)
Parthenolide and DMAPT increased PI-positive cells. (e) Time course of the effect induced by 15 mM parthenolide and DMAPT. (f) Influence of various inhibitors on the
production of PI-positive cells induced by 15 mM parthenolide or DMAPT for 16 h. After treatment, the cells (8 103 cells/well) were incubated for 15min with PI (2.0mg/ml
medium; red fluorescence) and the percentage of PI-positive cells was ascertained as described in Materials and Methods. In (a, b, e and f) values are the means of three
independent experiments±S.E. *Po0.01 versus untreated control. In (c) and (d) the results are representative of three independent experiments
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Anticancer activity of DMAPT in a xenograft model of
breast cancer. At first, a scratch assay in cell monolayer
was performed to study DMAPT (25 mM) effect on migration
of MDA-MB231 cells in vitro. Wound closure was measured
at various times and expressed as percentage of closure
area. The untreated MDA-MB231 cells exhibited already at
4 h a rapid wound closure activity completely healing the
scratched area at 16 h of incubation. This activity was instead
hampered in DMAPT-treated cells, which showed a
significant delay in wound healing (Figures 6a and b).
To ascertain whether 25 mM DMAPT can affect epithelial-
mesenchymal transition, we examined DMAPT effect on
vimentin level, a widely used mesenchymal marker. Untreated
MDA-MB231 cells expressed a high level of vimentin, which
was lowered by DMAPT treatment by 60% and 78% at 4 and
8 h, respectively (Figure 6c).
To demonstrate the effectiveness in vivo of DMAPT on
breast cancer we implanted xenografts of MDA-MB231 cells
in nude mice. When tumours became palpable with a size of
200 mm3, mice were randomised into two groups of 10
animals each. The treated group received daily DMAPT
(50 mg/Kg), solubilised in ethanol, by oral gavage, while the
untreated group received daily ethanol alone. DMAPT
treatment markedly reduced tumour volume by 40.3% on
day 7 and 48.3% on day 15, when compared with tumours of
the untreated group (Figure 7a). Long-term administration of
DMAPT was well tolerated in mice. No sign of toxicity was
apparent, such as weight loss or organ toxicity upon gross
examination. In particular, histological analyses revealed the
lack of abnormalities in liver, oesophagus and kidney of
treated mice. Moreover, the Kaplan–Meier survival curve
(Figure 7b) showed a significant increase in the median
survival time which enhanced from 12 days for the control
mice to 28 days.
Immunohistochemical analyses were performed using
sections of tumours removed from mice of both the groups
on days 16, 20 and 24 of treatment. Analyses conducted on
sections of tumours removed on 16th day are reported in
Figure 7c. Quantitative analyses (Figure 7d) performed by an
image analysing system43 demonstrated that DMAPT
treatment markedly reduced the level of VEGF, which is
involved in tumour angiogenesis, and that of MMP-2 and
MMP-9, two modulators of extracellular matrix remodelling.
Finally, in line with the results found in cultured cells, p65 level
decreased by DMAPT treatment, while p-JNK level markedly
enhanced.
To ascertain DMAPT effectiveness in reducing lung
metastasis, investigations were performed on mice of both
the groups, killed on 16, 20 and 24 days of treatment.
The relative area of lung metastasis was calculated using an
image analysing system. The analyses for mice killed on 16th
day of treatment (Figure 7e) showed that in treated mice about
5.7±0.5% of the lung area was replaced with cancer, while in
the controls this area was equal to 17.0±0.9%.
Figure 5 Parthenolide stimulates autophagic process in MDA-MB231 cells. (a–c) Detection of autophagic vacuoles with MDC test. Cells (8 103 cells/well) were treated
for various times with 15mM parthenolide with or without inhibitors. At the end, the cells were incubated with 50 mM MDC for 10min. Cell morphology was visualised with a
Leica microscope with fluorescence filter for DAPI. MDC-labelled autophagic vacuoles appear as distinct dot-like structures distributed in the cytoplasm. (a) Fluorescent
images showing positivity to MDC test at various times of treatment. At least five areas were scanned for each well and characteristic images for each condition are shown.
Micrographs were acquired at a magnification of  400. Scale bar, 10mm. (b) Quantification of the percentage of punctuated MDC stained cells measured at various times of
exposure to parthenolide. (c) The influence of various inhibitors on the positivity to MDC test. (d) Western blotting analysis showing that parthenolide favoured conversion of
LC3-I to LC3-II and increased the level of beclin-1. In (a) and (d), the results are representative of three independent experiments. In (b) and (c), values are the means of three
independent experiments±S.E. *Po0.01 versus untreated control
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Discussion
This paper investigates about the molecular mechanisms by
which parthenolide and its soluble analogue DMAPT reduced
in vitro viability of MDA-MB231 cells, which are hormone-
insensitive human breast cancer cells. Furthermore, we
ascertained the effect in vivo of DMAPT on tumour xenografts
derived from MDA-MB231 cells.
We employed in general 25 mM parthenolide or DMAPT for
in vitro experiments, except for experiments concerning Ca2þ
level, ROS generation, MDC and PI tests, when 15 mM was
employed for both the drugs, because in these cases
the lower concentration permitted to better appreciate the
differences between the various conditions tested.
We demonstrate that parthenolide stimulated ROS
generation, autophagic process and cell necrosis. ROS
generation was higher in the first hours of treatment, when
the drug induced superoxide anion production by stimulating
NOX activity, an effect which was suppressed by apocynin, a
specific inhibitor of NOX. Our observation agrees with the
finding of Sun et al.,26 showing that parthenolide activates
NOX in prostate cancer cells. Moreover, as BAPTA-AM, an
intracellular calcium chelator, prevented production of super-
oxide anion by parthenolide, we suggest that enhancement of
cytosolic Ca2þ was required for NOX stimulation. Partheno-
lide itself most likely enhanced cytosolic Ca2þ level, because
it behaves as a SERCA inhibitor.44 Finally, Ca2þ could
stimulate NOX favouring activation of RAC-145 and its
consequent migration from the cytoplasm to the membrane
where it induces assembly of various NOX subunits. More-
over, parthenolide stimulated RIP-1 expression, another
event involved in the activation of NOX-1.46
ROS generation induced by parthenolide caused two
important consequences: (1) activation of JNK, an effect
prevented by inhibitors of ROS generation, such as NAC and
apocynin; (2) a marked decrement in DNA-binding activity
of p65 with the consequent reduction of activity of NF-kB, a
transcription factor that supports tumour cell viability.
After the first hours of treatment, ROS level declined until
16 h. In the second phase, ROS partially derived by
dysfunction of mitochondrial activity, as suggested by
the finding that Rotenone and FCCP inhibited ROS generation
at 8 h.
ROS production induced by parthenolide stimulated auto-
phagic process already at the first hours of exposure. This
conclusion was suggested by the findings that the antioxidant
NAC prevented the cells from the increment in beclin-1
expression and the conversion of LC3-I to LC3-II. It seems
that ROS are essential for autophagy as they regulate Atg4, a
cysteine protease involved in the process.47 Moreover, JNK
and RIP-1 exerted a stimulatory role in this process, as their
specific inhibitors SP600125 and Nec-1 prevented both
positivity to MDC test and enhancement in LC3-II level.
These findings are in accordance with the observation that
JNK upregulates beclin-141 and favours its release from
Bcl-242, while RIP-1 increases LC3-II.48 Finally, as 3-MA and
wortmannin, two inhibitors of PI3K, prevented autophagic
process induced by parthenolide, we suggested that also
PI3K is involved in the stimulation of autophagy.
An important consequence of the enhanced and persistent
production of ROS was a remarkable decrement in the levels
of both free thiols and free GSH, which fell at 16 h to very low
values. GSH depletion could be responsible for mitochondrial
depolarisation observed already after 12 h of treatment by
Figure 6 DMAPT inhibits MDA-MB231 cell motility. (a–b) Cells grown in monolayer were scratched with a pipet tip and then treated with 25 mM DMAPT. Cell motility was
assessed by light microscopy and micrographs were taken at 4, 8 and 16 h, respectively. (a) Representative images of the scratch wound area were taken immediately after
wounding and at the indicated times. Scale bar, 100mm. (b) The histogram represents the percentage of wound closure. The scratched area was determined by Image J
software as described in Materials and Methods. Data are presented as the percentage of area populated by cells between 4 and 16 h. (c) DMAPT lowered the level of
mesenchymal marker vimentin. Cells were treated for 4, 8 and 16 h with 25 mM DMAPT, then cell lysates were prepared and subjected to western blotting as reported in
Materials and Methods. In (a) and (c), the results are representative of three independent experiments. In (b), values are the means of three independent experiments±S.E.
*Po0.01 versus untreated control
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Figure 7 The effect of DMAPT on xenograft models of breast cancer. (a) The effect of DMAPT on tumor growth. After 8 days of tumour establishment, mice (n¼ 10) were
treated by oral gavage with DMAPT 50mg/Kg/daily. Progression profile of tumour growth was compared with that of control mice treated with vehicle alone. (b) Kaplan–Meier
analysis. Mice treated with DMAPT showed prolonged survival when compared with mice treated with vehicle alone. (c) Immunohistochemical staining for VEGF, MMP-2,
MMP-9, p65, p-JNK in MDA-MB231 xenografts. Tumours were examined at day 16 after treatment initiation. Original magnification  400. Scale bar, 10mm. (d) Quantitative
data showed that the level of VEGF, MMP-2, MMP-9 and p65 were decreased after DMAPT treatment, while the level of p-JNK was increased. (e) Metastasis in untreated and
DMAPT-treated animals. Haematoxylin and eosin staining of lungs of control and treated mice at 16 days of treatment, showing that metastasis was lower in DMAPT-treated
mice compared with untreated animals. Lung metastasis were indicated by solid arrows. Scale bar, 100mm. In (c) and (e), the results are representative of three independent
experiments. In (d), values are the means of three independent experiments±S.E.
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analysis with the fluorescent dye JC-1. This conclusion
agrees with the finding of Zhang et al.13 that ROS and GSH
oxidation are involved in the control of Dcm. As a close
consequence of Dcm dissipation, mitochondrial function
appeared compromised. Therefore, between 12–20 h of
treatment the number of PI-positive cells rapidly increased,
suggesting that necrotic events became predominant at this
stage. In accordance with these considerations, addition of
NAC abrogated both dissipation of Dcm and positivity to PI.
Also Nec-1 markedly reduced positivity to PI, suggesting that
the increment of RIP-1 has an important role in the induction of
necrosis.
The increment of RIP-1 level was most likely caused by the
decrement of its cleavage by caspase 8. Parthenolide in fact
decreased pro-caspase 8 level but the cleaved forms of
caspase 8 were not observed until 16 h of exposure.
Conversely, the drug markedly increased c-FLIPS level.
These findings suggested, in accordance with Feoktistova
et al.,49 that the catalytic activity of the ripoptosome complex
in RIP-1 cleavage was repressed.
Figure 8 summarises the molecular mechanism by which
parthenolide induced death of MDA-MB231 cells. Also
DMAPT induces cytotoxic effects on MDA-MB231 cells
through a similar mechanism. Therefore, as DMAPT is more
soluble than parthenolide it was employed for in vivo
experiments.
The present article shows that DMAPT in vivo markedly
reduced the growth of xenografts derived from MDA-MB231
cells and significantly enhanced survival of treated mice, while
no sign of toxicity were apparent. Immunohistochemical
analyses showed that DMAPT increased in vivo p-JNK level,
while decreased that of the NF-kB component p65, likewise to
the effects found in vitro. Moreover, the treatment markedly
lowered the levels of factors involved in angiogenesis (VEGF)
and in the production of metastasis (MMP-2 and MMP-9).
These results agree with the observation50 that the decrease
in NF-kB activity downregulates both VEGF and
metalloproteinases and consequently represents an obstacle
to the production of metastasis. Finally, in line with the results
reported by Sweeney et al.18 and with our observation that
DMAPT hampered in vitro cell migration, we demonstrated
that lung metastases were markedly diminished in DMAPT-
treated mice.
Taken together, our results suggest that DMAPT can be a
candidate for TNBC therapy.
Moreover, the effectiveness of parthenolide in vivo could be
improved by using the fumarate salt of DMAPT, which exhibits
a good solubility in water.21 Finally, another strategy to
improve the cytotoxic activity of parthenolide on breast cancer
cells could consist in its combination with other compounds
capable of sensitising the cells to parthenolide action.
Materials and Methods
Chemicals and reagents. Parthenolide was supplied by Sigma-Aldrich
(Milan, Italy). Stock solution of parthenolide was prepared in dimethyl
sulfoxide (DMSO) and diluted to final concentration in the culture medium. Final
concentration of DMSO employed as vehicle never exceeded 0.04% and had no
discernible effects on MDA-MB231 cells in comparison with the control.
All reagents were purchased from Sigma-Aldrich, except for benzyloxycarbonyl-
Val-Ala-Asp (OMe)-fluoromethylketone (z-VAD-fmk), which was supplied from
Promega (Milan, Italy).
Cell cultures. MDA-MB231 cells, obtained from ‘Istituto Scientifico Tumori’
(Genoa, Italy), were grown as monolayer in DMEM culture medium supplemented
with 10% heat-inactivated foetal calf serum, 2 mM glutamine and 1% non essential
amino acids, at 37 1C in a humidified atmosphere containing 5% CO2. After plating
on 96- or 6-well plates, cells were allowed to adhere overnight and then treated
with chemicals or vehicle only.
Cell viability and cell death assays. Cell viability was ascertained by
MTT method, a colorimetric assay for measuring the activity of mitochondrial
dehydrogenases that reduce the tetrazolium dye, MTT, to formazan. For these
experiments, cells (8 103/well) were plated in 200ml of DMEM in a 96-well plate
and treated for various times with parthenolide or DMAPT and other compounds.
At the end, 20ml of MTT solution (11mg/ml in PBS) were added and incubation
was protracted for another 2 h. Then the plate was centrifuged at 120 g for 5 min,
190ml of medium were removed, while 100ml of lysis buffer (20% sodium dodecyl
Figure 8 Schematic representation of parthenolide effect in MDA-MB231 cells. Parthenolide induces activation of NOX through a Ca2þ -dependent mechanism, and also
activation of ERK1/2 and RIP-1. All these events cause ROS production. ROS lead to activation of JNK and downregulation of NF-kB. Moreover, ROS, JNK and
RIP-1 stimulate autophagic process. Persistent ROS generation induces GSH depletion and consequently dissipation of Dcm and cell necrosis
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sulphate in 50% N,N-dimethylformamide) were added. The absorbance of the
formazan was measured by a microplate reader (OPSYS MR, Dynex
Technologies, Chantilly, VA, USA) at 540 nm with a reference wavelength of
630 nm.
In order to determine extensive membrane damage, the cells were stained with
PI, as suggested by Asare et al.51 In particular, cells (8 103/well) were incubated
in culture medium and treated for various times with parthenolide or DMAPT and
other compounds. Then PI (2.0mg/ml medium) was added and the incubation was
protracted for additional 15min. At the end, cell morphology was visualised by a
Leica DMR microscope equipped with a DC300F camera (Wetzlar, Germany) using
an appropriate filter to examine PI (rhodamine filter with excitation wavelength of
596 nm and emission wavelength of 620 nm). All the images were acquired by Leica
Q Fluoro Software. Cells with red fluorescence were counted and normalised to total
number of cells/field to calculate the percentage of PI-positive cells. Five fields/
condition were analysed.
Apoptotic and necrotic effects were studied by annexin V and PI co-staining using
the Annexin V-FITC/PI Apoptosis Detection Kit I (BD Biosciences Pharmingen, San
Diego, CA, USA), according to the manufacturer’s instructions. Fluorescence of the
cells (105 per condition) was analysed by flow cytometry on a Beckman Coulter
Epics XL flow cytometer (Brea, CA, USA).
Evaluation of ROS generation. Production of intracellular reactive oxygen
intermediates was measured using 5-(and-6)-carboxy-20,70-dichlorodihydro-
fluorescein diacetate (H2-DCFDA), a fluorochrome that passively diffuses into
cells. After cleavage of acetate groups by intracellular esterases, a fluorescent
adduct is produced by oxidation.52
MDA-MB231 cells (8 103/well) were incubated with parthenolide and other
effectors for various times. At the end the medium was removed, 100ml of 50mM
H2-DCFDA were added and incubation was protracted for 30min at 37 1C. Then the
medium was replaced with PBS and after 20min the fluorescence was directly
visualised by means of a fluorescence microscope using a FITC filter (excitation
wavelength of 485 nm and emission wavelength of 530 nm). Cells with green
fluorescence were counted and normalised to total number of cells/field to calculate
the percentage of cells producing ROS. Five fields/condition were analysed.
Measurement of superoxide production. The superoxide radical
production was assessed by using DHE, a fluorochrome that is oxidised by
superoxide to generate fluorescent ethidium that intercalates with nuclear DNA.53
MDA-MB231 cells (8 103/well) were incubated with parthenolide or other
effectors, then cells were centrifuged at 120 g for 5 min and culture medium was
replaced with a solution of DHE (20 mM) in PBS. The incubation was protracted for
10min and DHE-positive cells were analysed by fluorescence microscopy using an
excitation wavelength of 596 nm and an emission wavelength of 620 nm. All the
images were acquired by Leica Q Fluoro Software.
Measurement of calcium level. Cytosolic calcium level was measured
using Fluo-3AM13 as previously reported.19 Cells (2 105/well) were collected,
washed twice with cold calcium-free PBS and then incubated with 5mM Fluo-3AM
for 60min at 37 1C in darkness. Then the cells were analysed by flow cytometry on
a Beckman Coulter Epics XL flow cytometer using the Expo32 software (Beckman
Coulter, Brea, CA, USA).
Detection of autophagic vacuoles. Autophagic vacuoles were detected
by MDC,39,54 a phospholipidic-specific marker that selectively accumulates in
autophagosomes, which appear as distinct dot-like structures. After exposure to
parthenolide treatment, cells were incubated with MDC (50 mM) in PBS at 37 1C
for 10min, then washed in PBS and immediately analysed by fluorescence
microscopy by using DAPI filter (excitation wavelength of 372 nm and emission
wavelength of 456 nm). Micrographs were acquired by Leica Q Fluoro Software.
Measurement of intracellular thiols and GSH content. To measure
intracellular thiols,13 cells after the treatment were detached, washed in PBS and
resuspended in 30mM Tris HCl, 3 mM EDTA, pH 8.2. For determination of protein
thiols, aliquots were added to 25ml of 1.5 mM 5.50-dithiobis-(2-nitrobenzoic acid)
(DTNB, Ellman’s reagent) and 400ml methanol. After centrifugation at 3000 g for
5 min, 250ml of each supernatant were transferred in a 96-well plate and read at
400 nm. For the analysis of free thiol groups, aliquots were incubated with 25 ml
10% trichloroacetic acid and centrifuged. Each supernatant (50 ml) was transferred
in a 96-well plate in the presence of 200ml 0.2 M Tris HCl, pH 8.9 and 20ml DTNB.
Then the samples were read at 400 nm. The absorbance was determined by an
automatic ELISA plate reader. The final content of intracellular thiols was
expressed as nanomoles of SH groups per 105 cells.
The intracellular GSH content was measured using a commercial assay,
provided by OXIS Research (Portland, OR, USA). After treatment, the cells
(5 105/condition) were harvested, and centrifuged at 120 g for 8 min. The pellets
were washed in PBS and resuspended in 50ml metaphosphoric acid (5 g/100ml
distilled water) and centrifuged at 3000 g for 10min. GSH content was measured as
described by manufacturer’s instructions. Absorbance was read at 400 nm in a
96-well plate reader. The content of intracellular GSH was expressed as nanomoles
of GSH per 105 cells.
Measurement of NF-kB activity. NF-kB activity was evaluated by an
ELISA-based assay (Trans-AM NF-kB; Active Motif, Carlsbad, CA, USA) as
described by manufacturer’s protocol. Briefly, nuclear extracts were prepared as
previously reported55 using 3 105 cells/condition. Aliquots were placed in 96-well
plates coated with an oligonucleotide containing the NF-kB consensus sequence.
NF-kB activity was detected using a specific antibody for p65 subunit provided by
the kit.
Analysis of mitochondrial membrane potential. In order to study the
effect of parthenolide on mitochondrial membrane potential (Dcm), MDA-MB231
cells (8 103/well), after exposure to compounds, were treated for additional
15min with JC-1 staining solution56 and Dcm was evaluated as indicated in the
manufacturer’s protocol supplied by the Cayman Chemical Company (Ann Arbour,
MI, USA). Cells were visualised by a fluorescence microscope. Healthy cells with
polarised mitochondria were detected using an appropriate filter to examine
J-aggregates with red-orange fluorescence (rhodamine filter with excitation
wavelength of 596 nm and emission wavelength of 620 nm). Unhealthy cells were
detected using a filter to examine JC-1 monomers with green fluorescence (FITC
filter with excitation wavelength of 485 nm and emission wavelength of 530 nm).
For all determinations, fluorescence was visualised by means of a Leica DMR
microscope equipped with a DC300F camera (Wetzlar, Germany), using the Leica
Q Fluoro Software.
Western blotting analysis. Whole-cell lysates were prepared as previously
reported57 and protein concentration was determined by Lowry assay.58 Protein
samples (50mg/lane) were subjected to SDS polyacrylamide gel electrophoresis,
then transferred to a nitrocellulose membrane.
All western blotting analyses were performed using specific antibodies obtained
by Santa Cruz Biotechnology (Santa Cruz, CA, USA), except for anti-RIP-1
antibody, which was provided by Abcam (San Francisco, CA, USA), anti-beclin-1,
anti-caspase 3, 8 and 9 antibodies by Cell Signaling Technology (Beverly, MA, USA)
and anti-LC3 antibody by Novus Biologicals (Cambridge, UK).
Then detection was developed using secondary antibodies conjugated with
alkaline phosphatase.
Protein bands were visualised using 5-bromo-4-chloro-3-indolyl phosphate and
nitro blue tetrazolium (Promega Italia) and their intensity was quantified by
densitometric analysis using SMX Image software (Bio-Rad, Hercules, CA, USA).
The correct protein loading was ascertained by red Ponceau staining and
immunoblotting for b-actin. All the blots shown are representative of at least three
separate experiments.
Cell migration. Cell migration was studied by using an in vitro scratch assay.
MDA-MB231 cells (2 105/well) were seeded on 6-well tissue culture plates and
grown to 100% confluence. Wounds were created by scraping the monolayer of
cells with a sterile pipette tip, washed with PBS to remove the floating cells and
incubated with fresh medium in the presence or absence of DMAPT.
The images (five/field) of scratched area were captured (at  100 magnification)
using a Leica DMR microscope equipped with DC300F digital camera immediately
after wounding and at 4, 8 and 16 h after application of DMAPT. The images were
compared with estimate the effects of DMAPT on wound healing and the
percentage of closure area was calculated by Image J software.
Animals and subcutaneous implantation of tumours. Female
nude athymic mice (Fox1 nu/nu) aged 4 weeks were obtained from Harlan (Udine,
Italy) and allowed to acclimatise for 1 week.
Suspensions of 2 106 MDA-MB231 cells in 0.2 ml of PBS were inoculated into
the mammary fat pad. Eight days after inoculation, when tumours became palpable,
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mice were subdivided into two groups of 10 animals each being the tumour volumes
equally distributed between the two groups. One group of mice was treated daily
with 50mg/Kg DMAPT (Biomol, Plymouth Meeting, PA, USA) prepared in a solution
at 50% ethanol, administered by oral gavage. Control group received daily by oral
gavage vehicle alone. Tumour volumes were determined daily using calipers.
Primary tumour volumes were calculated with the formula: v¼ length  (width)2/2.
Mice were euthanised when tumour burden exceeded 10% of the animal normal
body weight, or when tumour ulcerates or other conditions of morbidity were
ascertained, in conformity with institutional guidelines which are in compliance with
national (D.L., 116 G.U., Suppl.40; 18 February 1992) and international laws and
policies (ECC Council Directive 86/609, OJ L358.1, 12 December 1987). This study
was authorised by Italian Ministry of Health.
Immunohistochemistry (IHC). Immunohistochemical studies were per-
formed on formalin-fixed paraffin-embedded tumour tissues. Serial sections (4mm
thick) were fixed on glass slides, washed in xylen and hydrated in different
(decreasing) concentrations of alcohol. For antigen retrieval the slides were heated
in sodium citrate solution (pH 6.0) at 96 1C for 20min. Endogenous peroxidase
activity was quenched with 3% hydrogen peroxide in methanol for 30min. Then
the slides were treated with 1% bovine serum albumin (BSA) for 30min and
incubated overnight at 4 1C in the presence of 0.1% BSA with one of the following
antibodies: mouse monoclonal p-JNK (1 : 50), mouse monoclonal NF-kB (p65)
(1 : 50), rabbit polyclonal MMP-2 (1 : 50), mouse monoclonal MMP-9 (1 : 50) and
mouse monoclonal VEGF (1 : 50). All these antibodies were provided by Santa
Cruz Biotechnology, except for VEGF antibody, which was provided by R&D
Systems (Minneapolis, MN, USA).
At the end, the sections were treated for 30min with secondary biotinylated
immunoglobulin anti-mouse, anti-rabbit and anti-goat antibody (DAKO, Glostrup,
Denmark). Then the sections were incubated with the streptavidin conjugated to
horseradish peroxidase for 1 h, followed by the chromogen 3-30 diamminobenzidine
tetrahydrochloride for 1min, counterstained with Mayer’s haematoxylin. Immuno-
reactivity of these antibodies was ascertained by means of the labelled streptavidin-
biotin method (LSAB; Dako) according to manufacturer’s instructions. All
immunostained sections were analysed at a  400 magnification (five fields)
under a Leica DMLB optical microscope. Digital images were then analysed by
Image J computer program42 to evaluate the percentage of positive area for all
antibodies used in immunohistochemistry analyses.
In order to study lung metastasis, lungs were removed from mice, after killing,
fixed in formalin, embedded in paraffin and stained with haematoxylin and eosin.
Three sections were obtained for each lung. The lung sections were examined at
 50 magnification and compared with sections obtained from control mice.
The percentage of positive area was analysed by NIS-Elements software
(Nikon Instruments, Florence, Italy).
Statistical analysis. Results are presented as means±S.E. Data were
analysed using Student’s t-test.
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